The binding of [ 125 I]-factor Xa to human umbilical vein endothelial cell (HUVEC) monolayers was studied. At 7ΠC, [ 125 I]-factor Xa bound to a single class of binding sites with a dissociation constant value of 6.6 { 0.8 nM and a binding site density of 57,460 { 5,200 sites/cell (n Γ 3). Associati
Regulatory mechanisms for thrombomodulin expression in human umbilical vein endothelial cells in vitro
β Scribed by Kazunori Hirokawa; Nobuo Aoki
- Publisher
- John Wiley and Sons
- Year
- 1991
- Tongue
- English
- Weight
- 935 KB
- Volume
- 147
- Category
- Article
- ISSN
- 0021-9541
No coin nor oath required. For personal study only.
β¦ Synopsis
It has been reported that thrombomodulin (TM) expression in endothelial cells is modulated by various agents. We investigated cellular regulatory mechanisms for TM expression in human umbilical vein endothelial cells (HUVECs), incubated with agents, by measuring the time course changes in surface TM activity, total TM antigen in cell lysates, and TM mRNA levels. While dibutyryl CAMP (3 mM) increased TM mRNA levels in HUVECs and was followed by increased TM activity, dibutyryl cGMP had no effect on TM activity. Phorbol myristate acetate (PMA) induced rapid loss of surface TM activity (-8 h) and later increased TM mRNA levels between 4 h and 40 h (maximum at 24 h), resulting in biphasic effects on TM activity. Tumor necrosis factor or interleukin-1 p suppressed surface TM activity and TM mRNA levels. lnternalizationidegradation of TM in HUVECs incubated with PMA or cytokines was suggested by co-culture with chloroquine. The decrease in surface TM activity observed was not caused by the release of TM molecules from the cells into the conditioned media. These results suggest that TM activity in HUVECs is modulated by independent mechanisms involving cytoplasmic TM mRNA levels and internalizationidegradation of TM molecules. These regulatory mechanisms may involve protein kinase A and protein kinase Cdependent mechanisms but are independent of protein kinase G.
π SIMILAR VOLUMES
## Abstract Current therapeutic approaches to treat cancer are often hampered by the lack of specificity of the drugs used for therapy. Scavidin, a novel fusion protein expressed on cell membranes, could be utilized for targeting of therapeutic molecules. Scavidin exploits the high binding affinity